We don’t support this browser anymore.
This means our website may not look and work as you would expect. Read more about browsers and how to update them here.

Skip to main content
  • Register
  • Help
  • Contact us

Pieris Pharmaceuticals Inc (PIRS) USD0.001

Sell:$3.41 Buy:$3.70 Change: $0.09 (2.57%)
Market closed |  Prices as at close on 25 January 2022 | Switch to live prices |
Sell:$3.41
Buy:$3.70
Change: $0.09 (2.57%)
Market closed |  Prices as at close on 25 January 2022 | Switch to live prices |
Sell:$3.41
Buy:$3.70
Change: $0.09 (2.57%)
Market closed |  Prices as at close on 25 January 2022 | Switch to live prices |
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

Pieris Pharmaceuticals, Inc. is a clinical-stage biotechnology company that discovers and develops Anticalin-based drugs to target validated disease pathways. The Company’s lead respiratory Anticalin-based drug candidate, PRS-060/AZD1402, which is antagonizes IL-4R alpha, thereby inhibiting by IL-4 and IL-13, two cytokines, small proteins mediating signaling between cells within the human body, known to be mediators in the inflammatory cascade that drive the pathogenesis of asthma and other inflammatory diseases. The lead IO Anticalin-based drug candidate in its pipeline, cinrebafusp alfa, which is designed to target the immune receptor 4-1BB and the tumor target HER2. Cinrebafusp alfa is a genetic fusion of a variant of an HER2-targeting antibody with an Anticalin protein specific for 4-1BB.

Contact details

Address:
255 STATE STREET, 9TH FLOOR
BOSTON
02109
United States
Telephone:
+1 (857) 2468998
Website:
https://www.pieris.com/

Important dates

Future events
There are no future events available.
Past events
There are no past events available.

General stock information

Short code:
PIRS
ISIN:
US7207951036
Market cap:
$240.69 million
Shares in issue:
72.06 million
Sector:
Biotechnology
Exchange:
NASDAQ
Country:
United States
Currency:
US dollar
Indices:
n/a

Key personnel

  • Stephen Yoder
    President, Chief Executive Officer, Director
  • Thomas Bures
    Chief Financial Officer, Senior Vice President
  • Hitto Kaufmann
    Senior Vice President, Chief Scientific Officer
  • Ahmed Mousa
    Senior Vice President, Chief Business Officer, General Counsel, Company Secretary
  • Tim Demuth
    Senior Vice President, Chief Medical Officer
  • Shane Olwill
    Senior Vice President, Chief Development Officer

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by Reuters.

Share

The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.